Nemes Rush Group’s iShares Biotechnology ETF IBB Stock Holding History

Nemes Rush Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$339	Sell	2 -16	-89%	-$2.74K	﹤0.01%	903
2025 Q4	$3.04K	Hold	18	–	–	﹤0.01%	678
2025 Q3	$2.6K	Buy	18 +16	+800%	+$2.18K	﹤0.01%	585
2025 Q2	$253	Sell	2 -6,379	-100%	-$783K	﹤0.01%	704
2025 Q1	$816K	Sell	6,381 -49	-0.8%	-$6.64K	0.1%	97
2024 Q4	$850K	Buy	6,430 +6,019	+1,464%	+$846K	0.11%	98
2024 Q3	$56.4K	Buy	+411	New	+$59.5K	0.01%	250
2024 Q2	–	Sell	-411	Closed	-$56.4K	–	641
2024 Q1	$56.4K	Sell	411 -1,956	-83%	-$267K	0.01%	259
2023 Q4	$322K	Buy	+2,367	New	+$289K	0.05%	136

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nemes Rush Group's IBB Position: Q1 2026 in Review

Nemes Rush Group reduced its iShares Biotechnology ETF (IBB) stake by 89% in Q1 2026, selling an estimated $2.74K and leaving 2 shares worth $339. The position accounts for ﹤0.01% of the portfolio, ranked #903.

Nemes Rush Group first reported a position in IBB in Q4 2023 and has held it in 9 quarters since. The position peaked at $850K in Q4 2024. 918 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Nemes Rush Group held 2 shares of iShares Biotechnology ETF worth $339 as of Q1 2026.
Nemes Rush Group sold 16 iShares Biotechnology ETF shares in Q1 2026, an estimated $2.74K.
iShares Biotechnology ETF made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #903 holding.
Nemes Rush Group first reported a position in iShares Biotechnology ETF in Q4 2023 and has held it in 9 quarters since.
Nemes Rush Group's iShares Biotechnology ETF position peaked at $850K in Q4 2024.
918 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.